Harnessing the Power of Diagnostics

Q: How will QIAGEN’s mission and focus evolve in the next few years, particularly in the context of global health challenges?

A: The evolution of diagnostics over the past 20 years has been remarkable, driven by new technologies that allow us to specifically target and identify viruses with precision. This revolution in molecular biology really took off thanks to QIAGEN. Over 30 years ago, conducting molecular biology in laboratories was a tedious and contamination-prone process because DNA particles could easily spread. QIAGEN changed that by standardizing the extraction of nucleic acids from various sample types. This breakthrough made molecular biology accessible, transforming the field globally.

Over time, we have continued to innovate. Initially, we worked mostly with life science companies and academic labs, helping them conduct research. But we soon transitioned into the clinical space, providing breakthrough solutions like HPV testing for women, and diagnostics for HIV, hepatitis, and tuberculosis. COVID-19 highlighted just how vital the company is. We developed solutions that reached patients worldwide, proving our role in public health. We believe that healthcare is a right, not just a business. No matter where people live, they deserve access to quality healthcare; no one should be left behind.

Q: What are QIAGEN’s strategic goals in Mexico and how does the country fit into the company’s broader global strategy?

A: For us, there are no small or large countries. While market sizes may differ, what is common across all countries is the shared presence of patients in need. In Latin America, we have direct operations in Mexico and Brazil. With nearly 130 million inhabitants, Mexico demands our full attention. Moreover, the country boasts solid R&D, with strong academic research taking place at its universities, creating fertile ground for innovation and partnerships.

Q: How does preventive medicine improve healthcare systems, and how does QIAGEN contribute to this approach?

A: Diagnostics hold immense power, providing critical information that influences the next steps in patient care. At the heart of preventive medicine is obtaining this information as early as possible to ensure the patient receives timely treatment. Preventive medicine empowers patients and healthcare providers by delivering critical information much earlier, enabling doctors and labs to initiate specific treatments that can save lives. Increasing spending on preventive medicine and diagnostics could reduce global healthcare costs by 10% to 20%, according to the World Health Organization (WHO). Hospitals worldwide allocate only 3% to 5% of their budgets to diagnostics, yet 70% of clinical decisions in hospitals rely on diagnostic results.

We have advanced technologies that allow us to detect cancer earlier in patients. Once detected, these technologies help monitor whether the treatment is effective. Furthermore, they enable us to detect any residual disease after the patient enters remission, ensuring careful, ongoing monitoring. One great advancement is the development of liquid biopsy technology, which allows us to detect cancer by analyzing circulating tumor DNA without the need for an invasive tissue biopsy. 

Q: Latent tuberculosis poses a particular concern for immunocompromised individuals. How does QIAGEN address the importance of accurate diagnosis for high-risk groups?

A: When someone’s immune system is weakened, they become more susceptible to infections like tuberculosis. In Mexico, the prevalence of tuberculosis is higher among people with diabetes than in other parts of Latin America, highlighting the need for targeted testing and early treatment.

Tuberculosis is one of the most dangerous silent killers, representing 1.6 million deaths annually, more than HIV and malaria combined. Many in Western Europe or North America believe tuberculosis is a disease of the past or only affects emerging countries, but cases are increasing in the United States and Canada. Despite being a treatable disease, it remains a serious global issue. The challenge is catching it early and providing treatment before it becomes a more significant threat.

Q: What are the key factors contributing to the resurgence of tuberculosis?

A: Many people are moving, whether for tourism or to seek better jobs and opportunities, which creates new environments for potential contamination. Poverty also plays a significant role. In Mexico, for example, the highest tuberculosis rates are found in poorer areas. 

Another key factor is drug resistance. The world is seeing more strains of tuberculosis that are resistant to treatment, making it harder to eradicate the disease, which is why research is so critical. Many members of the WHO and the United Nations pledged years ago to increase spending on tuberculosis, but none have met those commitments. Yet, tuberculosis continues to kill millions annually.

Q: What key factors have driven the company's growth to date?

A: People are our greatest asset. Without our 6,000 employees, we would not be where we are. It is essential to invest in their growth and provide opportunities. Building a company is about the people, not just the investors. The business environment is demanding, but it is vital to be fair, listen, and respect everyone, regardless of hierarchy. Flexibility, openness to learning, and constant adaptation are key to thriving in a fast-changing world.

Q: What are QIAGEN's key priorities and goals for the coming years, particularly in terms of expanding your product portfolio and strengthening your global presence?

A: We have much on our plate with our existing portfolio. The company remains committed to investing primarily in molecular solutions. We are likely the only company in the world that offers solutions across polymerase chain reaction (PCR), digital PCR and Next Generation Sequencing. 

We will continue investing in disease diagnosis and expanding globally. We are headquartered in the Netherlands and listed both in the European Union and the United States. But it is not possible to fully understand what is happening in countries like Mexico from the European Union. It is crucial to think both globally and locally. While central decisions are necessary at times, maintaining and expanding our presence in Latin America, especially in Brazil and Mexico, remains a key part of our vision for the future of healthcare.

QIAGEN provides molecular testing solutions globally, enabling researchers and clinicians to gain valuable insights from biological samples.